Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Announced definitive agreement to acquire 100% of Kashiv BioSciences, expanding biosimilars capabilities and portfolio.

• Acquisition aims to create a fully integrated global biosimilars leader, adding over 600 employees and four biologics facilities.

• Preliminary Q1 2026 results: $723M net revenue, $202M adjusted EBITDA, $0.27 adjusted EPS; full-year 2026 guidance raised to $3.05–$3.15B revenue and $740–$770M adjusted EBITDA.

• Transaction subject to shareholder and regulatory approvals; companies to operate independently until close.

• Forward-looking statements highlight anticipated synergies, growth, and risks related to the transaction.

Voting matters and shareholder proposals

• Shareholder approval required for the proposed acquisition of Kashiv BioSciences.

• Proxy materials and statements to be filed with the SEC; investors urged to review all documents when available.

Board of directors and corporate governance

• Directors and executive officers may participate in proxy solicitation for the acquisition.

• Information on directors, nominees, and related party transactions available in the 2026 annual meeting proxy statement.